Clinical Impact of Heparin Kinetics During Catheter Ablation of Atrial Fibrillation: Meta‐Analysis and Meta‐Regression
- 3 May 2016
- journal article
- research article
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 27 (6), 683-693
- https://doi.org/10.1111/jce.12975
Abstract
Anticoagulation for Ablation of Atrial Fibrillation IntroductionAppropriate activated clotting time (ACT) during catheter ablation of atrial fibrillation (CA-AF) is essential to minimize periprocedural complications. Methods and ResultsAn electronic search was performed using major databases. Outcomes were thromboembolic (TE) and bleeding complications according to ACT levels (seconds). Heparin dose (U/kg) and time (minutes) to achieve the target ACT was compared among patients receiving vitamin K antagonist (VKA) versus non-VKA oral anticoagulants (NOAC). Nineteen studies involving 7,150 patients were identified. Patients with ACT > 300 had less TE (OR, 0.51; 95% CI 0.35-0.74) and bleeding (OR, 0.70; 95% CI 0.60-0.83) compared to ACT < 300, when using any type of oral anticoagulation. The use of VKA was associated with reduced heparin requirements (mean dose: 157 U/kg vs. 209 U/kg, P < 0.03; SDM -0.86 [95% CI -1.39 to -0.33]), and with lower time to achieve the target ACT (mean time: 24 minutes vs. 49 minutes, P < 0.03; SDM -11.02 [95% CI -13.29 to -8.75]) compared to NOACs. No significant publication bias was found. ConclusionsPerforming CA-AF with a target ACT > 300 decreases the risk of TE without increasing the risk of bleeding. Patients receiving VKAs required less heparin and reached the target ACT faster compared to NOACs.Keywords
This publication has 33 references indexed in Scilit:
- The Incidence of Asymptomatic Cerebral Microthromboembolism after Atrial Fibrillation Ablation: Comparison of Warfarin and DabigatranPacing and Clinical Electrophysiology, 2013
- Use of Dabigatran for Periprocedural Anticoagulation in Patients Undergoing Catheter Ablation for Atrial FibrillationCirculation: Arrhythmia and Electrophysiology, 2013
- Dabigatran versus Warfarin Therapy for Uninterrupted Oral Anticoagulation During Atrial Fibrillation AblationJournal of Cardiovascular Electrophysiology, 2013
- The Optimal Range of International Normalized Ratio for Radiofrequency Catheter Ablation of Atrial Fibrillation During Therapeutic Anticoagulation With WarfarinCirculation: Arrhythmia and Electrophysiology, 2013
- Prevention of Periprocedural Ischemic Stroke and Management of Hemorrhagic Complications in Atrial Fibrillation Ablation Under Continuous Warfarin AdministrationJournal of Cardiovascular Electrophysiology, 2012
- Differences in intraprocedural ACTs with standardized heparin dosing during catheter ablation for atrial fibrillation in patients treated with dabigatran vs. patients on uninterrupted warfarinJournal of Interventional Cardiac Electrophysiology, 2012
- A comparison of bleeding complications post-ablation between warfarin and dabigatranJournal of Interventional Cardiac Electrophysiology, 2012
- 2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: Recommendations for Patient Selection, Procedural Techniques, Patient Management and Follow-up, Definitions, Endpoints, and Research Trial DesignHeart Rhythm, 2012
- Periprocedural Stroke and Management of Major Bleeding Complications in Patients Undergoing Catheter Ablation of Atrial FibrillationCirculation, 2010
- Random-effects model for meta-analysis of clinical trials: An updateContemporary Clinical Trials, 2007